Everolimus (RAD001) activity in renal and hepatocellular carcinoma cells resistant to sunitinib and sorafenib

被引：0
|
作者：
Serova, Maria [1 ,2 ]
Riveiro, Maria Eugenia [1 ,2 ]
Dokmak, Safi [1 ,2 ]
Faivre, Sandrine [1 ,2 ]
Raymond, Eric [1 ,2 ]
机构：
[1] Beaujon Univ Hosp, RayLab, U728, Clichy, France
[2] Beaujon Univ Hosp, Dept Med Oncol, Clichy, France
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-4488
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4488
引用
收藏
页数：1
相关论文
共 50 条
  • [41] <bold>A single arm phase Ib study of RAD001 and sunitinib in </bold>patients with advanced renal cell carcinoma (RCC).
    Turnbull, J. D.
    Armstrong, A. J.
    Morris, K.
    Wood, S. E. Yenser
    Voyles, S.
    Fesko, Y. A.
    George, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] UPDATED DATA FROM A PHASE 3 TRIAL OF EVEROLIMUS (RAD001) VERSUS PLACEBO IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Kay, A.
    Motzer, R. J.
    Figlin, R. A.
    Escudier, B.
    Oudard, S.
    Porta, C.
    Hutson, T. E.
    Bracarda, S.
    Hollaender, N.
    Urbanowitz, G.
    Ravaud, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 185 - 185
  • [43] Treatment of refractory metastatic renal cell carcinoma (RCC) with bevacizumab and RAD001
    Hershman, L. C.
    McMillan, A.
    Srinivas, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] The mTOR inhibitor RAD001 (everolimus) is active against multiple myeloma cells in vitro and in vivo
    Mitsiades, N
    McMullan, C
    Poulaki, V
    Negri, J
    Raje, N
    Kumar, S
    Sikoutri, D
    Hideshima, T
    Chauhan, D
    Richardson, PG
    Schlossman, RL
    Kung, AL
    Lane, H
    Munshi, NC
    Anderson, KC
    Mitsiades, CS
    BLOOD, 2004, 104 (11) : 418A - 418A
  • [45] EVEROLIMUS (RAD001) AND THE MTOR PATHWAY IN LOW-GRADE GLIOMAS
    Clarke, Jennifer L.
    Chang, Susan
    Phillips, Joanna
    Molinaro, Annette
    Berger, Mitchel
    Nelson, Sarah
    Haas-Kogan, Daphne
    NEURO-ONCOLOGY, 2014, 16
  • [46] A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (Everolimus) plus sorafenib for patients with metastatic renal cell cancer (MRCC)
    Giessinger, S.
    Amato, R. J.
    Jac, J.
    Saxena, S.
    Willis, J. P.
    Chiang, S. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] mTOR inhibition for relapsed or refractory Hodgkin lymphoma: Promising single agent activity with Everolimus (RAD001)
    Johnston, Patrick B.
    Ansell, Steven M.
    Colgan, Josph P.
    Habermann, Thomas M.
    Inwards, David J.
    Micallef, Lvana N. M.
    Porrata, Luis F.
    Reeder, Craig B.
    Roy, Vivek
    LaPlant, Betsy R.
    Wilzig, Thomas E.
    BLOOD, 2007, 110 (11) : 753A - 753A
  • [48] Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma
    T Haritunians
    A Mori
    J O'Kelly
    Q T Luong
    F J Giles
    H P Koeffler
    Leukemia, 2007, 21 : 333 - 339
  • [49] Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
    O'Reilly, Terence
    McSheehy, Paul M. J.
    TRANSLATIONAL ONCOLOGY, 2010, 3 (02): : 65 - 79
  • [50] Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity
    Ross, R. W.
    Manola, J.
    Oh, W. K.
    Ryan, C.
    Kim, J.
    Rastarhuyeva, I.
    Yap, J. T.
    Van Den Abbeele, A. D.
    Kantoff, P. W.
    Taplin, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345